CA2406790A1 - Sustained release formulations - Google Patents
Sustained release formulations Download PDFInfo
- Publication number
- CA2406790A1 CA2406790A1 CA002406790A CA2406790A CA2406790A1 CA 2406790 A1 CA2406790 A1 CA 2406790A1 CA 002406790 A CA002406790 A CA 002406790A CA 2406790 A CA2406790 A CA 2406790A CA 2406790 A1 CA2406790 A1 CA 2406790A1
- Authority
- CA
- Canada
- Prior art keywords
- sustained release
- release formulations
- growth hormone
- release preparation
- especially human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
Abstract
This invention provides sustained release preparation of growth hormone, especially human growth hormone.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19820900P | 2000-04-19 | 2000-04-19 | |
US60/198,209 | 2000-04-19 | ||
PCT/US2001/012909 WO2001078683A2 (en) | 2000-04-19 | 2001-04-19 | Sustained release formulations comprising growth hormone |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2406790A1 true CA2406790A1 (en) | 2001-10-25 |
CA2406790C CA2406790C (en) | 2009-07-07 |
Family
ID=22732439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002406790A Expired - Fee Related CA2406790C (en) | 2000-04-19 | 2001-04-19 | Sustained release formulations |
Country Status (11)
Country | Link |
---|---|
US (1) | US6992065B2 (en) |
EP (1) | EP1274459B1 (en) |
JP (1) | JP4361710B2 (en) |
AT (1) | ATE309822T1 (en) |
AU (2) | AU2001259111B2 (en) |
CA (1) | CA2406790C (en) |
DE (1) | DE60115005T2 (en) |
DK (1) | DK1274459T3 (en) |
ES (1) | ES2253375T3 (en) |
IL (1) | IL152360A0 (en) |
WO (1) | WO2001078683A2 (en) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4460892B2 (en) | 2001-06-21 | 2010-05-12 | ジェネンテック インコーポレイテッド | Sustained release composition |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
DE10242088A1 (en) * | 2002-09-11 | 2004-03-25 | Bayer Ag | Controlled release medicament, e.g. for parenteral administration of flupirtine, comprising drug, sucrose acetate-isobutyrate and mixture of solvents miscible and immiscible with sucrose acetate-isobutyrate |
JP4865330B2 (en) | 2002-12-13 | 2012-02-01 | デュレクト コーポレーション | Oral drug delivery system |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
JP2006512370A (en) * | 2002-12-19 | 2006-04-13 | アルザ・コーポレーション | A stable non-aqueous single phase gel and its formulation for delivery from an implantable device |
DE10312346A1 (en) * | 2003-03-20 | 2004-09-30 | Bayer Healthcare Ag | Controlled release system |
RU2006128593A (en) * | 2004-01-07 | 2008-02-20 | Тримерис, Инк. (Us) | SYNTHETIC PEPTIDES, Derivatives of the HR2 PROTEIN GP41 HIV, AND THEIR APPLICATION IN THERAPY FOR INHIBITING THE PERMISSION OF HUMAN IMMUNODEFICIENCY VIRUS |
PT2767292T (en) * | 2004-09-17 | 2016-11-23 | Durect Corp | Sustained local anesthetic composition containing saib |
JP2008528509A (en) * | 2005-01-21 | 2008-07-31 | アルザ コーポレイション | Therapeutic peptide formulation for coating microneedles with improved stability comprising at least one counter ion |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
JP2008528698A (en) * | 2005-02-03 | 2008-07-31 | インターシア セラピューティクス,インコーポレイティド | Implantable interferon-containing devices |
CN101309688B (en) * | 2005-05-23 | 2016-06-22 | 自然选择国际公司 | The compositions of sustained release Beta-alanine and method |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
TWI341844B (en) | 2006-02-02 | 2011-05-11 | Trimeris Inc | Hiv fusion inhibitor peptides with improved biological properties |
MX2008014870A (en) | 2006-05-30 | 2009-02-12 | Intarcia Therapeutics Inc | Two-piece, internal-channel osmotic delivery system flow modulator. |
ES2422864T3 (en) | 2006-08-09 | 2013-09-16 | Intarcia Therapeutics, Inc | Osmotic release systems and piston units |
ES2388355T3 (en) | 2006-11-03 | 2012-10-11 | Durect Corporation | Transdemic delivery systems comprising bupivacaine |
US20080140106A1 (en) * | 2006-12-12 | 2008-06-12 | Kimberly-Clark Worldwide, Inc. | Enhanced cuff sealing for endotracheal tubes |
AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
MX2009010689A (en) * | 2007-04-03 | 2009-12-14 | Trimeris Inc | Novel formulations for delivery of antiviral peptide therapeutics. |
WO2008133908A2 (en) | 2007-04-23 | 2008-11-06 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
CN101801405A (en) | 2007-08-07 | 2010-08-11 | 先进科技及再生医学有限责任公司 | Be contained in the protein formulations of the GDF-5 in the acidic aqueous solution |
MX2010003179A (en) * | 2007-09-25 | 2010-04-30 | Trimeris Inc | Methods of synthesis for therapeuthic anti-hiv peptides. |
US8114883B2 (en) | 2007-12-04 | 2012-02-14 | Landec Corporation | Polymer formulations for delivery of bioactive materials |
WO2009088414A2 (en) | 2007-12-06 | 2009-07-16 | Durect Corporation | Oral pharmaceutical dosage forms |
US20090181068A1 (en) | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
JP5718058B2 (en) | 2008-02-08 | 2015-05-13 | キューピーエス リミテッド ライアビリティ カンパニー | Composition for slow broadcast of protein or peptide |
EP2244679A4 (en) * | 2008-02-08 | 2013-10-09 | Qps Llc | Non-polymeric compositions for controlled drug delivery |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
WO2009129101A1 (en) | 2008-04-14 | 2009-10-22 | Advanced Technologies And Regenerative Medicine, Llc | Liquid buffered gdf-5 formulations |
US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
WO2011037623A1 (en) | 2009-09-28 | 2011-03-31 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
US9511122B2 (en) | 2009-12-15 | 2016-12-06 | Ascendis Pharma Growth Disorders Division A/S | Dry growth hormone composition transiently linked to a polymer carrier |
EP2643009A4 (en) * | 2010-11-24 | 2015-04-01 | Durect Corp | Biodegradable drug delivery composition |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
ITMI20110445A1 (en) * | 2011-03-22 | 2012-09-23 | Lo Li Pharma Srl | PHARMACEUTICAL FORMULATION INCLUDING INOSITOLO. |
CN103127514B (en) * | 2011-11-22 | 2014-07-02 | 朱成钢 | Medicine sustained-release suppository capable of internal injection |
CN102389571B (en) * | 2011-11-22 | 2013-04-24 | 朱成钢 | Medicine sustained-release suppository used for in-vivo injection |
US9572885B2 (en) | 2013-03-15 | 2017-02-21 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
CN105764491A (en) | 2013-12-09 | 2016-07-13 | 度瑞公司 | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
CN113598842A (en) | 2015-06-03 | 2021-11-05 | 因塔西亚制药公司 | Implant placement and removal system |
EP3458084B1 (en) | 2016-05-16 | 2020-04-01 | Intarcia Therapeutics, Inc | Glucagon-receptor selective polypeptides and methods of use thereof |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
EP3565580B1 (en) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel |
US11208736B2 (en) | 2017-09-25 | 2021-12-28 | Bolt Threads, Inc. | Methods of generating highly-crystalline recombinant spider silk protein fibers |
AU2019318216A1 (en) * | 2018-08-10 | 2021-03-11 | Bolt Threads, Inc. | Composition for a molded body |
CN115666621A (en) | 2020-01-13 | 2023-01-31 | 度勒科特公司 | Sustained release drug delivery systems with reduced impurities and related methods |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4016273A (en) * | 1975-07-16 | 1977-04-05 | American Cyanamid Company | Sustained release forms of certain oxazepines for parenteral administration |
DE2916711A1 (en) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blood coagulation factors and process for their manufacture |
US5411951A (en) * | 1984-10-04 | 1995-05-02 | Monsanto Company | Prolonged release of biologically active somatotropin |
IL79681A (en) | 1985-08-12 | 1991-06-10 | Int Minerals & Chem Corp | Transition metal complexes of growth hormones and their prolonged release compositions |
WO1989003671A1 (en) | 1987-10-29 | 1989-05-05 | Dainippon Pharmaceutical Co., Ltd. | Sustained-release preparation |
US5096885A (en) | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US4975271A (en) | 1988-12-19 | 1990-12-04 | Vipont Pharmaceutical, Inc. | Muscosal delivery systems for treatment of periodontal disease |
US5324520A (en) | 1988-12-19 | 1994-06-28 | Vipont Pharmaceutical, Inc. | Intragingival delivery systems for treatment of periodontal disease |
US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
US5487897A (en) | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
US5077049A (en) | 1989-07-24 | 1991-12-31 | Vipont Pharmaceutical, Inc. | Biodegradable system for regenerating the periodontium |
US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
US5133981A (en) | 1989-11-17 | 1992-07-28 | Atrix Laboratories, Inc. | Purification of benzophenanthridine alkaloids extracts from alkaloid extracts |
AU8935591A (en) | 1990-10-30 | 1992-05-26 | Alza Corporation | Drug delivery system and method |
US5416071A (en) | 1991-03-12 | 1995-05-16 | Takeda Chemical Industries, Ltd. | Water-soluble composition for sustained-release containing epo and hyaluronic acid |
WO1992017200A2 (en) | 1991-03-28 | 1992-10-15 | Genentech, Inc. | Stable growth hormone metal ion formulations |
US5252338A (en) | 1991-06-27 | 1993-10-12 | Alza Corporation | Therapy delayed |
AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5711968A (en) | 1994-07-25 | 1998-01-27 | Alkermes Controlled Therapeutics, Inc. | Composition and method for the controlled release of metal cation-stabilized interferon |
US5242910A (en) | 1992-10-13 | 1993-09-07 | The Procter & Gamble Company | Sustained release compositions for treating periodontal disease |
PT674506E (en) | 1992-12-02 | 2001-01-31 | Alkermes Inc | MICROSPHERES CONTAINING GROWTH HORMONE WITH CONTROLLED LIBERATION |
DK0686045T3 (en) | 1993-02-23 | 2001-03-05 | Genentech Inc | Stabilization of organic solvent-treated polypeptides with an adjuvant |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6080429A (en) | 1993-10-25 | 2000-06-27 | Genentech, Inc. | Method for drying microspheres |
EP0668073B1 (en) | 1994-02-21 | 1999-04-14 | Takeda Chemical Industries, Ltd. | Polyester matrix for a pharmaceutical sustained-release preparation |
US5556905A (en) | 1994-03-30 | 1996-09-17 | Reilly Industries, Inc. | Physically-modified degradable thermoplastic compositions |
CA2582666C (en) | 1994-04-08 | 2010-05-25 | Qlt Usa, Inc. | Controlled release implant |
US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US5904935A (en) | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
US6413536B1 (en) | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
US5968542A (en) | 1995-06-07 | 1999-10-19 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system as a device |
US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
CA2192773C (en) | 1995-12-15 | 2008-09-23 | Hiroaki Okada | Production of sustained-release preparation for injection |
US5792477A (en) | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
US5932547A (en) | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
US5981489A (en) | 1996-07-18 | 1999-11-09 | Alza Corporation | Non-aqueous protic peptide formulations |
US5851229A (en) | 1996-09-13 | 1998-12-22 | Meadox Medicals, Inc. | Bioresorbable sealants for porous vascular grafts |
EP0839525B1 (en) | 1996-10-31 | 2004-08-04 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
ATE203157T1 (en) | 1996-12-20 | 2001-08-15 | Alza Corp | INJECTABLE DEPOSIT GEL PREPARATION AND PRODUCTION METHOD |
EP0946169B1 (en) | 1996-12-20 | 2003-02-26 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
US6051558A (en) | 1997-05-28 | 2000-04-18 | Southern Biosystems, Inc. | Compositions suitable for controlled release of the hormone GnRH and its analogs |
US6113947A (en) | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
US6191107B1 (en) | 1997-09-26 | 2001-02-20 | Takeda Chemical Industries, Ltd. | Complex of human growth hormone and zinc |
US6039977A (en) | 1997-12-09 | 2000-03-21 | Alza Corporation | Pharmaceutical hydrogel formulations, and associated drug delivery devices and methods |
CN1173742C (en) * | 1997-12-26 | 2004-11-03 | 山之内制药株式会社 | Sustained release medicinal compositions |
US6174547B1 (en) | 1999-07-14 | 2001-01-16 | Alza Corporation | Dosage form comprising liquid formulation |
US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
KR100491815B1 (en) | 1998-12-23 | 2005-05-27 | 암젠 인코포레이티드 | Pharmaceutical composition comprising polyol/oil suspensions for the sustained release of proteins and process for preparing thereof |
WO2000078335A1 (en) * | 1999-06-18 | 2000-12-28 | Southern Biosystems, Inc. | COMPOSITIONS FOR CONTROLLED RELEASE OF THE HORMONE GnRH AND ITS ANALOGS |
US6245806B1 (en) | 1999-08-03 | 2001-06-12 | Merck & Co., Inc. | HIV integrase inhibitors |
US6458387B1 (en) | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
AU2001271491A1 (en) * | 2000-06-26 | 2002-01-08 | Monsanto Technology Llc | Non-aqueous surfactant-containing formulations for extended release of somatotropin |
-
2001
- 2001-04-19 AT AT01932596T patent/ATE309822T1/en not_active IP Right Cessation
- 2001-04-19 EP EP01932596A patent/EP1274459B1/en not_active Expired - Lifetime
- 2001-04-19 AU AU2001259111A patent/AU2001259111B2/en not_active Ceased
- 2001-04-19 DE DE60115005T patent/DE60115005T2/en not_active Expired - Lifetime
- 2001-04-19 JP JP2001575984A patent/JP4361710B2/en not_active Expired - Fee Related
- 2001-04-19 AU AU5911101A patent/AU5911101A/en active Pending
- 2001-04-19 ES ES01932596T patent/ES2253375T3/en not_active Expired - Lifetime
- 2001-04-19 CA CA002406790A patent/CA2406790C/en not_active Expired - Fee Related
- 2001-04-19 IL IL15236001A patent/IL152360A0/en not_active IP Right Cessation
- 2001-04-19 US US09/839,684 patent/US6992065B2/en not_active Expired - Fee Related
- 2001-04-19 DK DK01932596T patent/DK1274459T3/en active
- 2001-04-19 WO PCT/US2001/012909 patent/WO2001078683A2/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
WO2001078683A2 (en) | 2001-10-25 |
CA2406790C (en) | 2009-07-07 |
DE60115005T2 (en) | 2006-07-27 |
EP1274459A2 (en) | 2003-01-15 |
IL152360A0 (en) | 2003-05-29 |
WO2001078683A3 (en) | 2002-05-30 |
DE60115005D1 (en) | 2005-12-22 |
AU2001259111B2 (en) | 2005-12-08 |
DK1274459T3 (en) | 2006-02-06 |
US6992065B2 (en) | 2006-01-31 |
AU5911101A (en) | 2001-10-30 |
JP2004500423A (en) | 2004-01-08 |
ATE309822T1 (en) | 2005-12-15 |
JP4361710B2 (en) | 2009-11-11 |
ES2253375T3 (en) | 2006-06-01 |
US20020001631A1 (en) | 2002-01-03 |
EP1274459B1 (en) | 2005-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2406790A1 (en) | Sustained release formulations | |
AU2001276608A1 (en) | Sustained release formulations for growth hormone secretagogues | |
AU7862200A (en) | Flip-wing tissue retainer | |
AU2001279972A1 (en) | Pesticidal formulations | |
AU2002305578A1 (en) | Applanation tonometer | |
AU2002234476A1 (en) | Medical aerosol formulations | |
MXPA03003235A (en) | Delayed release pharmaceutical formulations. | |
AU2001266075A1 (en) | Combinations of active ingredients, which exhibit insecticidal and acaricidal properties | |
GB0100658D0 (en) | Crystallisation - resistant aqueous growth hormone formulations | |
AU2002317759A1 (en) | Ophthalmoscope | |
MXPA03002569A (en) | Controlled release formulations for oral administration. | |
AU2001264042A1 (en) | 1,4-diazabicyclo(3.2.2)nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof | |
AU2001235595A1 (en) | 4-heteroaryl-1,4-diazabicyclo(3.2.2)nonane, preparation and therapeutic use thereof | |
WO2002036145A3 (en) | Kahalalide f formulation | |
EP2017269A3 (en) | A pharmaceutical compodition comprising form II crystalline Ritonavir and a preparation thereof | |
AU2002340573A1 (en) | Powdery active ingredient formulations | |
WO2001078682A3 (en) | Sustained release drug compositions | |
AU6386801A (en) | System for the release of active ingredients | |
AU2002358264A1 (en) | High-strength low-viscosity agricultural formulations | |
AU2001274877A1 (en) | Pest treatment composition | |
IL152533A0 (en) | NOVEL FORMULATIONS OF alpha-2,4-DISULFOPHENYL-N-TERTBUTYLNITRONE | |
AU2362701A (en) | Fragrance or flavor formulation | |
AU2001295855A1 (en) | Chocolate spread | |
AU1556000A (en) | Composition allowing predefined and controlled release of active ingredient, preparation thereof and use | |
HUP0301158A3 (en) | Preparation of 4-metayl-2,3,5,6-tetrafluorbenzyl alcohol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20150420 |